|
2007 Conference Publication Immunosuppression (IST) can be safely ceased during chemotherapy for PTLD in renal transplant patientsMollee, Peter, Hourigan, Matthew, Johnson, David, Jones, Mark, Isbel, Nikki, Hawley, Carmel, Marlton, Paula, Gandhi, Maher, Campbell, Scott and Gill, Devinder (2007). Immunosuppression (IST) can be safely ceased during chemotherapy for PTLD in renal transplant patients. 49th Annual Meeting of the American-Society-of-Hematology, Atlanta, GA USA, 8-11 December 2007. Washington, DC USA: American Society of Hematology. |
|
2007 Journal Article Diagnostic and prognostic utility of the serum free light chain assay in patients with AL amyloidosisMorris, K. L., Tate, J. R., Gill, D., Kennedy, G., Wellwood, J., Marlton, P., Bird, R., Mills, A. K. and Molle, P. (2007). Diagnostic and prognostic utility of the serum free light chain assay in patients with AL amyloidosis. Internal Medicine Journal, 37 (7), 456-463. doi: 10.1111/j.1445-5994.2007.01368.x |
|
2007 Journal Article Palifermin-induced Acanthosis NigricansLane, S. W., Manoharan, S. and Mollee, P. N. (2007). Palifermin-induced Acanthosis Nigricans. Internal Medicine Journal, 37 (6), 417-418. doi: 10.1111/j.1445-5994.2007.01340.x |
|
2007 Journal Article Immunity, homing and efficacy of allogeneic adoptive immunotherapy for posttransplant lymphoproliferative disordersGandhi, M., Wilkie, G. M., Dua, U., Mollee, P., Grimmett, K., Williams, T., Whitaker, N., Gill, D. and Crawford, D. (2007). Immunity, homing and efficacy of allogeneic adoptive immunotherapy for posttransplant lymphoproliferative disorders. American Journal of Transplantation, 7 (5), 1293-1299. doi: 10.1111/j.1600-6143.2007.01796.x |
|
2007 Journal Article Analytical performance of serum free light-chains assayTate, Jillian R., Mollee, Peter, Dimeski, Goce, Carter, Andrew C. and Gill, Devinder (2007). Analytical performance of serum free light-chains assay. Clinica Chimica Acta, 380 (1-2), 250-251. doi: 10.1016/j.cca.2007.02.004 |
|
2007 Journal Article Analytical performance of serum free light-chain assay during monitoring of patients with monoclonal light-chain diseasesTate, Jillian R., Mollee, Peter, Dimeski, Goce, Carter, Andrew C. and Gill, Devinder (2007). Analytical performance of serum free light-chain assay during monitoring of patients with monoclonal light-chain diseases. Clinica Chimica Acta, 376 (1-2), 30-36. doi: 10.1016/j.cca.2006.07.011 |
|
2007 Journal Article Epstein-Barr virus T-cell immunity despite rituximabNehring, Angela K., Dua, Ujjwal, Mollee, Peter, Gill, Devinder, Grimmett, Karen, Khanna, Rajiv, Moss, Denis and Gandhi, Maher K. (2007). Epstein-Barr virus T-cell immunity despite rituximab. British Journal of Haematology, 136 (4), 628-632. doi: 10.1111/j.1365-2141.2006.06482.x |
|
2007 Journal Article The International Prognostic Index: the “gold-standard” in post-transplant lymphoproliferative disorders after renal transplantationHourigan, M. J., Mollee, P. N., Gill, D. S., Doecke, J., Norris, D., Johnson, D. W. and Gandhi, M. K.. (2007). The International Prognostic Index: the “gold-standard” in post-transplant lymphoproliferative disorders after renal transplantation. American Journal of Transplantation, 7, 399-399. |
|
2007 Conference Publication Immunosuppression (IST) Can Be Safely Ceased during Chemotherapy for PTLD in Renal Transplant PatientsHourigan, Matthew J., Johnson, David W., Jones, Mark, Gill, Devinder S., Isbel, Nikki, Hawley, Carmel M., Marlton, Paula, Ghandhi, Maher, Campbell, Scott B. and Mollee, Peter (2007). Immunosuppression (IST) Can Be Safely Ceased during Chemotherapy for PTLD in Renal Transplant Patients. American Transplant Congress 2007, USA, 5-9 May 2007. UK: Wiley-Blackwell Publising Ltd.. doi: 10.1111/j.1600-6143.2007.01811.x |
|
2007 Conference Publication JAK2V617F mutation status predicts thrombotic complications, including arterial thrombosis, in patients with essential thrombocytosis (ET)Weston, H, Bird, R, Griffiths, V, Jones, M, Grimmett, K, Saal, R, Mills, AK, Gill, D, Marlton, P and Mollee, P (2007). JAK2V617F mutation status predicts thrombotic complications, including arterial thrombosis, in patients with essential thrombocytosis (ET). 49th Annual Meeting of the American-Society-of-Hematology, Atlanta Ga, Dec 08-11, 2007. WASHINGTON: AMER SOC HEMATOLOGY. |
|
2007 Conference Publication Immunosuppression (IST) can be safely ceased during chemotherapy for PTLD in renal transplant patientsHourigan, Matthew J., Johnson, David W., Jones, Mark, Gill, Devinder S., Isbel, Nikki, Hawley, Carmel M., Marlton, Paula, Gandhi, Maher, Campbell, Scott B. and Mollee, Peter (2007). Immunosuppression (IST) can be safely ceased during chemotherapy for PTLD in renal transplant patients. American Transplant Congress, San Francisco, CA, USA, 5-9 May 2007. Oxford, England: Wiley-Blackwell. doi: 10.1111/j.1600-6143.2007.01811.x |
|
2007 Conference Publication Efficacy and safety of sequential treatment with rituximab and CHOP chemotherapy in B-cell PTLD: Results of a prospective international phase II studyTrappe, R., Choquet, S., Oertel, S., LeBlond, V., Ekman, T., Sender, M., Mollee, P, Reinke, P., Lehmkuhl, H., Hummel, M., Jonas, S., Neuhaus, R., Salles, G., Morschhauser, F., Jaccard, A., Anagnostopoulos, I., Raphael, M. and Riess, H. (2007). Efficacy and safety of sequential treatment with rituximab and CHOP chemotherapy in B-cell PTLD: Results of a prospective international phase II study. Annual American Transplant Congress, San Francisco, CA, United States, 5 - 9 May 2007. Malden, MA, United States: Wiley-Blackwell Publishing. doi: 10.1111/j.1600-6143.2007.01811.x |
|
2006 Journal Article Increased Mortality with FLA Compared with ADE Chemotherapy in High-risk AML (Letter to the Editor)Lane, Steven W., Marlton, Paula and Mollee, Peter N. (2006). Increased Mortality with FLA Compared with ADE Chemotherapy in High-risk AML (Letter to the Editor). Blood, 108 (12), 3950-3951. doi: 10.1182/blood-2006-06-032680 |
|
2006 Conference Publication Prolonged hematologic toxicity from the Hyper-CVAD regimen; manifestations, frequency, and natural history in a cohort of 125 consecutive patientsGill, Saar, Lane, Steven, Crawford, Julie, Mollee, Peter, Marlton, Paula, Cull, Gavin, Prince, Miles and Seymour, John Francis (2006). Prolonged hematologic toxicity from the Hyper-CVAD regimen; manifestations, frequency, and natural history in a cohort of 125 consecutive patients. 48th Annual Meeting of the American-Society-of-Hematology, Orlando, FL, United States, 9-12 December 2006. Washington, DC, United States: American Society of Hematology. doi: 10.1182/blood.v108.11.2441.2441 |
|
2006 Journal Article Characterisation and prognostic significance of WT-1 gene expression in acute myeloid leukemia (AML)Lane, Steven W., Saal, Russell, Negus, Suzanne, Mollee, Peter, Mather, M., Gill, Devinder, Mills, Anthony K., Bird, Robert J., Hourigan, Matthew J., Jones, Mark and Marlton, Paula (2006). Characterisation and prognostic significance of WT-1 gene expression in acute myeloid leukemia (AML). Blood, 108 (11). doi: 10.1182/blood.v108.11.2313.2313 |
|
2006 Journal Article The Hyper-CVAD chemotherapy regimen has an adverse long-term impact on the ability to mobilize peripheral blood stem cells, which can be readily circumvented by using the early cycles for mobilizationKeane, Colm, Gibbs, Simon, Seymour, John F., Mills, Anthony K ., Grimmett, Karen, Van Kuilenberg, Rosita, Russell, Saal, Gill, Devinder, Prince, H. Miles, Marlton, Paula and Mollee, Peter (2006). The Hyper-CVAD chemotherapy regimen has an adverse long-term impact on the ability to mobilize peripheral blood stem cells, which can be readily circumvented by using the early cycles for mobilization. Hematological Oncology, 24 (3), 159-163. doi: 10.1002/hon.784 |
|
2006 Journal Article Safety and efficacy of pegfilgrastim compared to granulocyte colony stimulating factor (G-CSF)supporting a dose-intensive, rapidly cycling anti-metabolite containing chemotherapy regimen (Hyper-CVAD) for lymphoid malignancyLane, Steven W., Crawford, Julie, Kenealy, Melita, Cull, Gavin, Seymour, John F., Prince, H. Miles, Marlton, Paula, Gill, Devinder and Mollee, Peter N. (2006). Safety and efficacy of pegfilgrastim compared to granulocyte colony stimulating factor (G-CSF)supporting a dose-intensive, rapidly cycling anti-metabolite containing chemotherapy regimen (Hyper-CVAD) for lymphoid malignancy. Leukemia and Lymphoma, 47 (9), 1813-1817. doi: 10.1080/10428190600632832 |
|
2006 Journal Article The effect of the Hyper-CVAD chemotherapy regimen on fertility and ovarian functionSeshadri, T., Hourigan, M. J., Wolf, M., Mollee, P. N. and Seymour, J. F. (2006). The effect of the Hyper-CVAD chemotherapy regimen on fertility and ovarian function. Leukemia Research, 30 (4), 483-485. doi: 10.1016/j.leukres.2005.08.014 |
|
2006 Journal Article A phase II study of thalidomide and vinblastine for palliative patients with Hodgkin's lymphomaKuruvilla, John, Song, Kevin, Mollee, Peter, Panzarella, Tony, McCrae, Jan, Nagy, Tracy, Crump, Michael and Keating, Armand (2006). A phase II study of thalidomide and vinblastine for palliative patients with Hodgkin's lymphoma. Hematology, 11 (1), 25-29. doi: 10.1080/10245330500276592 |
|
2006 Journal Article Plasma Epstein-Barr virus (EBV) DNA is a biomarker for EBV-positive Hodgkin's lymphomaGandhi, M. K., Lambley, E., Burrows, J., Dua, U., Elliott, S., Shaw, P. J., Prince, H. M., Wolf, M., Clarke, K., Underhill, C., Mills, T., Mollee, P., Gill, D., Marlton, P., Seymour, J. F. and Khanna, R. (2006). Plasma Epstein-Barr virus (EBV) DNA is a biomarker for EBV-positive Hodgkin's lymphoma. Clinical Cancer Research, 12 (2), 460-464. doi: 10.1158/1078-0432.CCR-05-2008 |
